Summary
Metabolic syndrome (MetS) is a serious threat to public health worldwide with an increased risk of developing type 2 diabetes, cardiovascular diseases and all-cause morbidity and mortality. In this study, a urinary metabolomic approach was performed on high performance liquid chromatography quadrupole time-of-flight mass spectrometry to discriminate 36 male MetS patients and 36 sex and age matched healthy controls. Pattern recognition analyses (principal component analysis and orthogonal projections to latent structures discriminate analysis) commonly demonstrated the difference between MetS patients and no-MetS subjects. This study found 8 metabolites that showed significant changes in patients with MetS, including branch-chain and aromatic amino acids (leucine, tyrosine, phenylalanine and tryptophan), short-chain acylcanitine (tiglylcarnitine), tricarboxylic acid (TCA) cycle intermediate (cis-aconitic acid) and glucuronidated products (cortolone-3-glucuronide and tetrahydroaldosterone-3-glucuronide). The candidate biomarkers revealed in this study could be useful in providing clues for further research focusing on the in-depth investigation of the cause of and cure for MetS.
Similar content being viewed by others
References
Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet, 2005, 366(9491):1059–1062
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009,120(16):1640–1645
Gu D, Reynolds K, Wu X, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet, 2005,365(9468):1398–1405
Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol, 2007,49(4):403–414
Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2005,28(9):2289–2304
Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet, 2010,375(9710):181–183
Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest, 2006,116(7): 1784–1792
Esteghamati A, Zandieh A, Zandieh B, et al. Leptin cut-off values for determination of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Endocrine, 2011,40(1):117–123
Timpson NJ, Lawlor DA, Harbord RM, et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet, 2005,366(9501):1954–1959
Nicholson JK, Wilson ID. Opinion: understanding ‘global’ systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov, 2003,2(8): 668–676
Raamsdonk LM, Teusink B, Broadhurst D, et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol, 2001,19(1):45–50
An J, Muoio DM, Shiota M, et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med, 2004,10(3): 268–274
Ong ES, Zou L, Li S, et al. Metabolic profiling in colorectal cancer reveals signature metabolic shifts during tumorigenesis. Mol Cell Proteomics, 2010 [PMID: 20147338]
Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med, 2011,17(4):448–453
Lv H, Hung CS, Chaturvedi KS, et al. Development of an integrated metabolomic profiling approach for infectious diseases research. Analyst, 2011,136(22):4752–4763
Othman A, Rutti MF, Ernst D, et al. Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? Diabetologia, 2012,55(2):421–431
Zhang T, Wu X, Ke C, et al. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J Proteome Res, 2013,12(1):505–512
Dunn WB, Wilson ID, Nicholls AW, et al. The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans. Bioanalysis, 2012,4(18):2249–2264
Bijlsma S, Bobeldijk I, Verheij ER, et al. Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal Chem, 2006,78(2): 567–574
An Z, Chen Y, Zhang R, et al. Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer. J Proteome Res, 2010,9(8):4071–4081
Zhu Z, Wang H, Shang Q, et al. Time course analysis of candida albicans metabolites during biofilm development. J Proteome Res, 2013,12(6):2375–2385
Zhang F, Jia Z, Gao P, et al. Metabonomics study of atherosclerosis rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry. Talanta, 2009,79(3):836–844
Wurtz P, Tiainen M, Makinen VP, et al. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care, 2012,35(8):1749–1756
Wurtz P, Soininen P, Kangas AJ, et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care, 2013,36(3):648–655
Patti M E, Brambilla E, Luzi L, et al. Bidirectional modulation of insulin action by amino acids. J Clin Invest, 1998,101(7):1519–1529
Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab, 2009,9(4):311–326
Soares-da-Silva P, Vieira-Coelho MA, Pinto-do OP, et al. Studies on the nature of the antagonistic actions of dopamine and 5-hydroxytryptamine in renal tissues. Hypertens Res, 1995, 18(Suppl 1):S47–S51
Hirose M, Tomoda F, Koike T, et al. Imbalance of renal production between 5-hydroxytryptamine and dopamine in patients with essential hypertension complicated by microalbuminuria. Am J Hypertens, 2013,26(2):227–233
Adams S H. Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr, 2011,2(6):445–456
Mihalik SJ, Goodpaster BH, Kelley DE, et al. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring), 2010,18(9):1695–1700
Schooneman MG, Vaz FM, Houten SM, et al. Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes, 2013,62(1):1–8
Sharma S, Sud N, Wiseman DA, et al. Altered carnitine homeostasis is associated with decreased mitochondrial function and altered nitric oxide signaling in lambs with pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol, 2008, 294(1):L46–56
Satapati S, Sunny N E, Kucejova B, et al. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J Lipid Res, 2012, 53(6):1080–1092
Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis, 2009,13(4): 545–563
Catania VA, Carrillo MC. Intestinal phase II detoxification systems: effect of low-protein diet in weanling rats. Toxicol Lett, 1990,54(2–3):263–270
Xu J, Kulkarni SR, Li L, et al. UDP-glucuronosyltransferase expression in mouse liver is increased in obesity- and fasting-induced steatosis. Drug Metab Dispos, 2012,40(2):259–266
Guan HP, Goldstein JL, Brown MS, et al. Accelerated fatty acid oxidation in muscle averts fasting-induced hepatic steatosis in SJL/J mice. J Biol Chem, 2009,284(36): 24644–24652
Osabe M, Sugatani J, Fukuyama T, et al. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab Dispos, 2008,36(2): 294–302
Author information
Authors and Affiliations
Corresponding author
Additional information
This project was supported by a grant from the Tianjin Scientific and Technological Support Key Projects (No. 08ZCGYSF01500) and the Tianjin Department of Science & Technology.
Rights and permissions
About this article
Cite this article
Yu, Zr., Ning, Y., Yu, H. et al. A HPLC-Q-TOF-MS-based urinary metabolomic approach to identification of potential biomarkers of metabolic syndrome. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 34, 276–283 (2014). https://doi.org/10.1007/s11596-014-1271-7
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-014-1271-7